Development of other microtubule-stabilizer families: the epothilones and their derivatives

Anti-Cancer Drugs

Volumn 25, Issue 5, 2014, Pages 599-609

  Brogdon, Cynthia F ^a   Lee, Francis Y ^a   Canetta, Renzo M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Anthracycline; Chemotherapy; Epothilones; Ixabepilone; Metastatic breast cancer; Microtubule stabilizing; Microtubules; Refractory; Resistant; Taxanes

Indexed keywords

BIOLOGICAL MARKER; EPOTHILONE B; EPOTHILONE DERIVATIVE; IXABEPILONE; SAGOPILONE; ANTINEOPLASTIC AGENT; TUBULIN MODULATOR;

BREAST CANCER; CANCER CHEMOTHERAPY; CELL CYCLE; CELL FUNCTION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; MICROTUBULE; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; ANIMAL; BREAST TUMOR; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECT; DRUG RESISTANCE; FEMALE; METABOLISM; METASTASIS; MITOSIS; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; HUMANS; MICROTUBULES; MITOSIS; NEOPLASM METASTASIS; NEOPLASMS; TUBULIN MODULATORS;

EID: 84891646354     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000071     Document Type: Review

References (109)

1. Gillet JP, Gottesman MM. Mechanisms of multidrug resistance in cancer. Methods Mol Biol 2010; 596:47-76.
2. DeVita VT, Lawrence TS, Rosenberg SA. Cancer: principles & practice of oncology. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
3. Halaven (eribulin mesylate). Prescribing information. Woodcliff Lake, NJ: Eisai Inc 2013; Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2013/201532s006lbl.pdf. [Accessed 25 November 2013].
4. Taxol (paclitaxel). Prescribing information. Princeton, NJ: Bristol-Myers Squibb Company 2011; Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/020262s049lbl.pdf. [Accessed 25 November 2013].
5. Taxotere (docetaxel). Prescribing information. Bridgewater, NJ: Sanofi-Aventis US, LLC 2013; Available at: http://www.accessdata. fda.gov/drugsatfda-docs/label/2007/020449s045lbl.pdf. [Accessed 25 November 2013].
6. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277:665-667.
7. Arbuck SG, Christian MC, Fisherman JS, Cazenave LA, Sarosy G, Suffness M, et al. Clinical development of Taxol. J Natl Cancer Inst Monogr 1993; 15:11-24.
8. Yardley DA. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes. Clin Breast Cancer 2008; 8:487-492.
9. Rivera E, Gomez H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res 2010; 12 (Suppl 2):S2.
10. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55:2325-2333.
11. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 2000; 97:2904-2909.
12. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on alpha-, beta-tubulin by electron crystallography. Science 2004; 305:866-869.
13. Verrills NM, Flemming CL, Liu M, Ivery MT, Cobon GS, Norris MD, et al. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interaction. Chem Biol 2003; 10:597-607.
14. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272:17118-17125.
15. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubulestabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol). J Biol Chem 1997; 272:2534-2541.
16. Chou TC, Zhang XG, Balog A, Su DS, Meng D, Savin K, et al. Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc Natl Acad Sci USA 1998; 95:9642-9647.
17. Chou TC, O'Connor OA, Tong WP, Guan Y, Zhang ZG, Stachel SJ, et al. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumour xenografts in nude mice. Proc Natl Acad Sci USA 2001; 98:8113-8118.
18. Bode CJ, Gupta ML, Reiff EA, Suprenant KA, Georg GI, Himes RH. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 2002; 41:3870-3874.
19. Lee FYF, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor activity. Clin Cancer Res 2001; 7:1429-1437.
20. Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 2009; 63:201-212.
21. Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2002; 2:123-148.
22. Mekhail T, Chung C, Holden S, Bukowski RM, Eckhardt SG, Cunningham M, et al. Phase I trial of novel epothilone B analog BMS-310705 IV q 21 days. Proc Am Soc Clin Oncol 2003; 22:129 (abstract 515).
23. Sessa C, Perotti A, Malossi A, Capri G, Cresta S, De Braud F, et al. Phase I and pharmacokinetic (PK) study of the novel epothilone BMS-310705 in patients (pts) with advanced solid cancer. Proc Am Soc Clin Oncol 2003; 2:130 (abstract 519).
24. Alexander EJ, Rosa E, Bolos J, Castaner R. Sagopilone. Drugs Fut 2008; 33:496-505.
25. Sessa C, Perotti A, Lladò A, Cresta S, Capri G, Voi M, et al. Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Ann Oncol 2007; 18:1548-1553.
26. Kavallaris M, Kuo DYS, Burkhart CA, Regl DL, Norris MD, Haber M, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 1997; 100: 1282-1293.
27. Seve P, Mackey J, Isaac S, Trédan O, Souquet PJ, Pérol M, et al. Class III b-tubulin expression in tumor cells predicts response and outcome of patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005; 4:2001-2007.
28. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, et al. Class III β-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005; 11:298-305.
29. Burkhart CA, Kavallaris M, Horwitz SB. The role of β-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta 2001; 1471:1-9.
30. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR. Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 1998; 77:562-566.
31. Li B, Staren ED, Iwamura T, Appert H, Howard J. Mechanisms of taxotererelated drug resistance in pancreatic carcinoma. J Surg Res 2001; 99:179-186.
32. Jordan MA, Miller H, Ni L, Castenada S, Inigo I, Kan D, et al. The Pat-21 breast cancer model derived from a patient with primary taxol resistance recapitulates the phenotype of its origin, has altered h-tubulin expression and is sensitive to ixabepilone. Presented at the 97th AACR Annual Meeting, 1-5 April 2006, Washington, District of Columbia, late-breaking poster session (abstract LB-280).
33. Dumontet C, Jordan MA, Lee FY. Ixabepilone: targeting bIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 2009; 8:17-25.
34. Ferrandina G, Zannoni G, Martinelli E, Paglia A, Gallotta V, Mozzetti S, et al. Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res 2006; 12: 2774-2779.
35. Hasegawa S, Miyoshi Y, Egawa C, Ishitobi M, Taguchi T, Tamaki Y, et al. Prediction of response to docetaxel by quantitative analysis of class I and III β-tubulin isotype mRNA expression in human breast cancers. Clin Cancer Res 2003; 9:2992-2997.
36. Paradiso A, Mangia A, Chiriatti A, Tommasi S, Zito A, Latorre A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 2005; 16 (Suppl 4):iv14-iv19.
37. Edelman MJ, Schneider CP, Tsai CM, Kim HT, Quoix E, Luft AV, et al. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status. J Clin Oncol 2013; 31:1990-1996.
38. Horak CE, Pusztai L, Xing G, Trifan OC, Saura C, Tseng LM, et al. Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage breast cancer. Clin Cancer Res 2013; 19:1587-1595.
39. Edelman MJ, Shvartsbeyn M. Epothilones in development for non-small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance. Clin Lung Cancer 2012; 13:171-180.
40. Ixempra (ixabepilone). Prescribing information. Princeton, NJ: Bristol-Myers Squibb Company 2011; Available at: http://www. accessdata.fda.gov/drugsatfda-docs/label/2011/022065s006lbl.pdf. [Accessed 25 November 2013].
41. Rocha Lima CM, Lin EH, Kim GP, Giguere JK, Marshall J, Zalupski M, et al. A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer. Gastrointest Cancer Res 2012; 5:155-160.
42. Moulder S, Li H, Wang M, Gradishar WJ, Perez EA, Sparano JA, et al. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: An Eastern Cooperative Oncology Group Trial. Breast Cancer Res Treat 2010; 119:663-667.
43. Chuang E, Wiener N, Christos P, Kessler R, Cobham M, Donovan D, et al. Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary. Ann Oncol 2010; 21:2075-2080.
44. Roché H, Zambetti M, Dalenc F, Govi S, Gladieff L, Mudenda B, et al. Phase Ib study of ixabepilone (I) in combination with epirubicin (E) in women with metastatic breast cancer (abstract). J Clin Oncol 2008; 26 (Suppl):1058.
45. Roché H, De Benedictis E, Cottura E, Govi S, Dalenc F, Locatelli A, et al. A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer. Clin Breast Cancer 2012; 12:167-174.
46. Rugo HS, Campone M, Amadori D, Wardley AM, Aldrighetti D, Conte PF, et al. Randomized phase II study of weekly versus every 3 week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC): final results (abstract). J Clin Oncol 2010; 28 (Suppl):1040.
47. Yardley DA, Barton J Jr, Dickson N, Shipley D, Drosick DR, Hendricks C, et al. Sorafenib plus ixabepilone as first-line treatment for patients with HER2-negative metastatic breast cancer: preliminary results of the phase II trial of the Sarah Cannon Research Institute. Cancer Res 2012; 72 (Suppl):463s.
48. Schwartzberg LS, Tauer KW, Schnell FM, Hermann R, Rubin P, Christianson D, et al. Phase II trial of ixabepilone (Ixa) and dasatinib (D) for treatment of metastatic breast cancer (MBC). Cancer Res 2012; 72 (Suppl):481s.
49. Thomas E, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25: 5210-5217.
50. Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat 2010; 122:409-418.
51. Rugo HS, Campone M, Amadori D, Aldrighetti D, Conte P, Wardley A, et al. A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Res Treat 2013; 139:411-419.
52. Rugo HS, Barry WT, Moreno-Aspitia A, Lyss AP, Cirrincione C, Mayer EL, et al. CALGB 40502/NCCTG N063H: randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nabpaclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC) (abstract). J Clin Oncol 2012; 30 (Suppl):CRA1002.
53. Vahdat LT, Garcia AA, Vogel C, Pellegrino C, Lindquist DL, Iannotti N, et al. Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat 2013; 140:341-351.
54. Conte P, Roche H, Perez E, Sparano J, Xu B, Jassem J, et al. Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large phase III studies (abstract). Cancer Res 2009; 69 (Suppl):6114.
55. Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/ HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat 2010; 121:261-271.
56. Roché H, Li R, Ro J, Vrdoljak E, Rahman ZU, Medina C, et al. Ixabepilone plus capecitabine improves progression-free survival in patients with metastatic breast cancer resistant to taxanes: a pooled analysis from two phase III trials (abstract). Cancer Res 2009; 69 (Suppl):2015.
57. Rugo HS, Roche H, Thomas E, Blackwell K, Chung H, Lerzo G, et al. Ixabepilone plus capecitabine vs capecitabine in patients with triplenegative tumors: a pooled analysis of patients from two large phase III clinical studies (abstract). Cancer Res 2009; 69 (Suppl):3057.
58. Yardley DA. Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents. Clin Breast Cancer 2010; 10:64-71.
59. Fountzilas G, Kotoula V, Pectasides D, Kouvatseas G, Timotheadou E, Bobos M, et al. Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized noncomparative phase II trial. PLoS One 2013; 8:e69256.
60. Tolaney SM, Najita J, Sperinde J, Huang W, Chen WY, Savoie J, et al. A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer. Ann Oncol 2013; 24:1841-1847.
61. Jassem J, Fein L, Karwal M, Campone M, Peck R, Poulart V, et al. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies. Breast 2012; 21:89-94.
62. Cortes J, Vidal M. Beyond taxanes: the next generation of microtubuletargeting agents. Breast Cancer Res Treat 2012; 133:821-830.
63. Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane and capecitabine. J Clin Oncol 2007; 25:3407-3414.
64. Thomas E, Tabernero J, Fornier M, Conté P, Fumoleau P, Lluch A, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007; 25:3399-3406.
65. Roché H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007; 25: 3415-3420.
66. Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005; 23:2726-2734.
67. Denduluri N, Low JA, Lee JJ, Berman AW, Walshe JM, Vatas U, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007; 25:3421-3427.
68. Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG, et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 2009; 27:526-534.
69. Saura C, Tseng LM, Chan S, Chacko RT, Campone M, Manikhas A, et al. Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of bIII-tubulin expression as a predictive marker. Oncologist 2013; 18:787-794.
70. Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C, et al. Randomized phase III trial of ixabepilone plus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010; 28:3256-3263.
71. Vahdat LT, Thomas ES, Roché HH, Hortobagyi GN, Sparano JA, Yelle L, et al. Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. Support Care Cancer 2012; 20:2661-2668.
72. Valero V, Vrdoljak E, Xu B, Thomas E, Gómez H, Manikhas A, et al. Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. Clin Breast Cancer 2012; 12:240-246.
73. Vansteenkiste J, Lara PN Jr, Le Chevalier T, Breton JL, Bonomi P, Sandler AB, et al. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinumbased chemotherapy. J ClinOncol2007; 25:3448-3455.
74. Liu G, Chen YH, Dipaola R, Carducci M, Wilding G. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clin Genitourin Cancer 2012; 10:99-105.
75. Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, et al. Ixabepilone, mitoxantrone, and prednisone for metastatic castrationresistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department of Defense Prostate Cancer Clinical Trials Consortium. Cancer 2011; 117:2419-2425.
76. Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, et al. Activity of second-line chemotherapy in docetaxelrefractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110:556-563.
77. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, et al. Multiinstitutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005; 23:1439-1446.
78. Kim YH, Muro K, Yasui H, Chen JS, Ryu MH, Park SH, et al. A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy. Cancer Chemother Pharmacol 2012; 70:583-590.
79. Ajani JA, Safran H, Bokemeyer C, Shah MA, Lenz HJ, Van Cutsem E, et al. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs 2006; 24:441-446.
80. Eng C, Kindler HL, Nattam S, Ansari RH, Kasza K, Wade-Oliver K, et al. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. Ann Oncol 2004; 15: 928-932.
81. Whitehead RP, McCoy S, Rivkin SE, Gross HM, Conrad ME, Doolittle GC, et al. A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs 2006; 24:515-520.
82. Fojo AT, Menefee ME, Poruchynsky M, Edgerly M, Mickley L, Li Ning Tapia E, et al. A translational study of ixabepilone (BMS-247550) in renal cell cancer (RCC): assessment of its activity and demonstration of target engagement in tumor cells. J Clin Oncol 2005; 23 (16S):4541.
83. Posadas EM, Undevia S, Colevas AD, Manchen E, Vokes EE, Sadler WM. A phase II study of ixabepilone (BMS 247550) in metastatic renal cell carcinoma. J Clin Oncol 2006; 24 (18S):14646.
84. Huang H, Menefee M, Edgerly M, Zhuang S, Kotz H, Poruchynsky M, et al. A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clin Cancer Res 2010; 16:1634-1641.
85. Pavlick AC, Millward M, Farrell K, Hamilton A, Broseus A, Haas N, et al. A phase II study of epothilone B analog (EpoB)-BMS 247550 (NSC#710428) in stage IV malignant melanoma. J Clin Oncol 2004; 22 (14S):7542.
86. Singh DA, Taber D, Ansari R, Lenz HJ, Agamah E, Nattam S, et al. A phase II trial of the epothilone B analog BMS-247550 in patients (pts) with hepatobiliary cancer (HBC): an updated analysis. J Clin Oncol 2006; 24 (Suppl):14050.
87. Dreicer R, Li S, Manola J, Haas NB, Roth BJ, Wilding G. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800). Cancer 2007; 110:759-763.
88. Dizon DS, Blessing JA, McMeekin DS, Sharma SK, Disilvestro P, Alvarez RD. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. JClinOncol2009; 27:3104-3108.
89. De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 2010; 28:149-153.
90. Agrawal M, Edgerly M, Fojo T, Kotz H. Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog. Gynecol Oncol 2003; 90:96-99.
91. Okuno S, Maples WJ, Mahoney MR, Fitch T, Stewart J, Fracasso PM, et al. Evaluation of epothilone B analog in advanced soft tissue sarcoma: a phase II study of the phase II consortium. J Clin Oncol 2005; 23:3069-3073.
92. Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, et al. New Approaches to Brain Tumor Therapy (NABTT) Consortium. A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas. J Neurooncol 2010; 100:261-268.
93. Jacobs S, Fox B, Krailo MD, Hartley G, Navid F, Wexler L, et al. Phase II trial of ixabepilone (BMS-247550) in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. J Clin Oncol 2008; 26 (15S):10026.
94. O'Reilly T, Wartmann M, Brueggen J, Allegrini PR, Floersheimer A, Maira M, McSheehy PM. Pharmacokinetic profile of the microtubule stabilizer5 patupilone in tumor-bearing rodents and comparison of anti-cancer activity with the other MTS in vitro and in vivo. Cancer Chemother Pharmacol 2008; 62:1045-1054.
95. Oehler C, Frei K, Rushing EJ, McSheehy PM, Weber D, Allegrini PR, et al. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial. Oncology 2012; 83:1-9.
96. Sanchez JM, Mellemgaard A, Perry M, Zatloukal P, Hamm J, Belani CP, et al. Efficacy and safety of patupilone in non-small cell lung cancer (NSCLC): a phase I/III trial. J Clin Oncol 2006; 24 (Suppl):390s (abstract 7104).
97. Zatloukal P, Mellemgaard A, Sanchez JM, Perry MC, Hamm JT. Activity of patupilone in advanced or metastatic non-small cell lung cancer (NSCLC): a phase II study. Ann Oncol 2008; 19 (Suppl 8):296P.
98. Chi KN, Beardsley E, Eigl BJ, Venner P, Hotte SJ, Winquist E, et al. A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Ann Oncol 2012; 23:53-58.
99. Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS Johri AR. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 2009; 20:492-497.
100. Smit WM, Sufliarsky J, Werner TL, Dizon DS, Wagnerová M, Hirte HW, et al. A phase II study of patupilone (EPO906) in patients with platinumresistant or platinum-refractory ovarian cancer. Clin Ovarian Gynecol Cancer [Accessed 18 November 2013]. doi: 10.1016/ j.cogc.2012.06.001. [Epub ahead of print].
101. Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinumrefractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol 2012; 30: 3841-3847.
102. Hoffmann J, Fichtner I, Lemm M, Lienau P, Hess-Stumpp H, Rotgeri A, et al. Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro-oncol 2009; 11:158-166.
103. Stupp R, Tosoni A, Bromberg JE, Hau P, Campone M, Gijtenbeek J, et al. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann Oncol 2011; 22:2144-2149.
104. Silvani A, Gaviani P, Fiumani A, Scaioli V, Lamperti E, Eoli M, et al. Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. J Neurooncol 2009; 95:61-64.
105. Heigener DF, von Pawel J, Eschbach C, Brune A, Schmittel A, Schmelter T, et al. Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer. Lung Cancer 2013; 80:319-325.
106. Beer TM, Smith DC, Hussain A, Alonso M, Wang J, Giurescu M, et al. Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. Br J Cancer 2012; 107:808-813.
107. Brunden KR, Ballatore C, Lee VM, Smith AB 3rd, Trojanowski JQ. Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans 2012; 40:661-666.
108. Ballatore C, Brunden KR, Huryn DM, Trojanowski JQ, Lee VM, Smith AB 3rd. Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies. J Med Chem 2012; 55:8979-8996.
109. Barten DM, Fanara P, Andorfer C, Hoque N, Wong PY, Husted KH, et al. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubulestabilizing agent BMS-241027. J Neurosci 2012; 32:7137-7145.